Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 1.00 |
| ▸ | TPO | P07202 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280952 | 1.00 | MPO (1.00) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL2288062 | 1.00 | MPO (1.00) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL1461291 | 0.82 | MPO (0.70) | MPOTPOALDH1A1HSD17B10PDE4A | |
| SCHEMBL1460900 | 0.81 | MPO (0.69) | MPOTPOALDH1A1HSD17B10KDM4E | |
| SCHEMBL29084974 | 0.76 | MPO (0.61) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL1962177 | 0.75 | MPO (0.59) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL3256669 | 0.75 | MPO (0.59) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL1959309 | 0.72 | MPO (0.56) | MPOTPOALDH1A1POLBHSD17B10 | |
| SCHEMBL10180927 | 0.71 | MPO (0.60) | MPOTPOHSD17B10PDE4AADORA2A | |
| SCHEMBL1373494 | 0.71 | PDE4A (0.74) | MPOTPOHSD17B10PDE4AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383158-B2 | Detection of high-risk unstable atherosclerotic plaque | THE HEART RESEARCH INSTITUTE LTD (AU) | 2025-08-12 | — | — | US | claimed |
| US-20240138701-A1 | DETECTION OF HIGH-RISK UNSTABLE ATHEROSCLEROTIC PLAQUE | THE HEART RESEARCH INSTITUTE LTD (AU) | 2024-05-02 | — | — | US | claimed |
| US-20210298611-A1 | DETECTION OF HIGH-RISK UNSTABLE ATHEROSCLEROTIC PLAQUE | VICTOR CHANG CARDIAC RES INSTITUTE (AU) | 2021-09-30 | — | — | US | claimed |
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| EP-1499613-B1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-19 | — | — | EP | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| CN-101062037-B | Process for their preparation of thioxanthine derivatives, their use | ASTRAZENECA AB | 2011-05-25 | — | — | CN | claimed |
| EP-2200616-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | claimed |
| CN-101062037-A | Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | claimed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | claimed |
| US-12383158-B2 | Detection of high-risk unstable atherosclerotic plaque | THE HEART RESEARCH INSTITUTE LTD (AU) | 2025-08-12 | — | — | US | disclosed |
| US-20240138701-A1 | DETECTION OF HIGH-RISK UNSTABLE ATHEROSCLEROTIC PLAQUE | THE HEART RESEARCH INSTITUTE LTD (AU) | 2024-05-02 | — | — | US | disclosed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885ALDH1A1 1797/4885 |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | MPO 1/4885TPO 5/4885ALDH1A1 178/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885ALDH1A1 1797/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | MPO 1/4885TPO 5/4885ALDH1A1 178/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | MPO 1/4885TPO 199/4885ALDH1A1 928/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885ALDH1A1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.